
Claims


[Claim 1] A compound having Formula I-1 or I-2:




[Compound I-1] [Compound I-2].

[Claim 2] The compound of claim 1, wherein the compound is amorphous, Form A, Form B, Form C, Form D, Form E or Form F of compound I-1, and the Form A, Form B, Form C, Form D, Form E or Form F is one of the following crystalline forms of compound I-1:


1) Form A having the following X-ray powder diffraction (XRPD) pattern;




2) Form B having the following thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) properties;




3) Form C having the following X-ray powder diffraction (XRPD) pattern;




4) Form D having the following X-ray powder diffraction (XRPD) pattern;



5) Form E having the following X-ray powder diffraction (XRPD) pattern; and




6) Form F having the following X-ray powder diffraction (XRPD) pattern.




[Claim 3] The compound of claim 2, wherein the compound is amorphous of compound I-1.

[Claim 4] The compound of claim 3, wherein the amorphous of compound I-1 has the following X-ray powder diffraction (XRPD) pattern:



[Claim 5] A pharmaceutical composition for inflammatory bowel disease comprising the compound I-1 in an amorphous form, wherein upon storage at 40°C at a relative humidity of 75% or at 25°C at a relative humidity of 60% for 6 month, the pharmaceutical composition has less than 10 wt % of the compound I-1 in a crystalline form:



[Compound I-1].